Reduction of Remifentanil-related Complications

Phase 4 Not yet recruiting 160 enrolled Seoul National University Hospital

RandomizedParallel-groupTriple-blindPrevention

Summary

This study is intended to evaluate the effect of decreasing the maximum plasma concentration target of remifentanil of the Target Controlled Infusion system on the the incidence of major and minor side-effects.

Timeline

Start: 2024-11-01
Primary completion: 2025-12-01
Completion: 2026-12-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Remifentanil	Small molecule	—	—

Indications

No indication recorded.